Painweek 2012 Booth Presentation: Strategies to Detect and Prevent Adulteration and Substitution in Urine Drug Testing


Urine is often the preferred specimen for drug testing due to noninvasive collection and because urine testing is readily available and inexpensive. However, pain management patients may adulterate or substitute urine to mimic compliance to drug therapy. This presentation will discuss strategies for detecting and preventing urine adulteration, as well as alternate specimen types that can be used for drug screening and which are less susceptible to adulteration/substitution.

Originally presented on September 07, 2012, in Las Vegas, Nevada.

Lecture Presenter

Kamisha Johnson-Davis, PhD, DABCC

Kamisha Johnson-Davis, PhD, DABCC

Medical Director, Clinical Toxicology Laboratory
ARUP Laboratories
Assistant Professor of Pathology
University of Utah School of Medicine

Dr. Johnson-Davis is the medical director of the Clinical Toxicology Laboratory at ARUP and an assistant professor of pathology at the University of Utah School of Medicine. Dr. Johnson-Davis received her PhD in pharmacology at the University of Utah and is board certified in clinical chemistry by the American Board of Clinical Chemistry. She completed her postdoctoral fellowship in clinical chemistry at the University of Utah, Department of Pathology, and was a postdoctoral research associate at the Center of Human Toxicology at the University of Utah. Dr. Johnson-Davis is a member of various professional societies, including the Academy of Clinical Laboratory Physicians and Scientists and the American Association for Clinical Chemistry.

Sponsored by:

University of Utah School of Medicine, and ARUP Laboratories